Revvity Inc (RVTY) Stock Forecast & Price Target

Revvity exhibits a robust financial outlook due to its strategic transition from TST to IGRA, which is expected to drive market growth by a few hundred basis points annually. The company's diversified portfolio, including a high-growth software segment that contributes approximately 10% of sales and a leading life sciences reagents franchise bolstered by acquisitions, enhances its profitability potential and provides valuable cross-selling opportunities. Additionally, Revvity's operational leverage and consistent growth in key markets, particularly in the United States, position the company for sustained above-market growth in reagents, autoimmune testing, and software solutions.

Revvity faces significant challenges in its China market, particularly within the Immunodiagnostics segment, which experienced a decline of double digits in the second quarter of 2025, resulting in total revenue from China decreasing by mid-single digits. The company may be further impacted by ongoing economic conditions and industry funding cuts, leading to reduced customer demand and a potential slowdown in growth and market share. Additionally, macroeconomic factors could disrupt Revvity's supply chain, introducing inflationary pressures and labor shortages that hinder its ability to deliver products effectively.